BeOne Medicines (ONC) Long-Term Debt Issuances (2015 - 2025)
BeOne Medicines (ONC) posted quarterly Long-Term Debt Issuances of $26.0 million for Q4 2025, up 187.2% year-over-year from $9.1 million in Q4 2024, and down 97.06% quarter-over-quarter from $885.0 million in Q3 2025.
BeOne Medicines (ONC) Long-Term Debt Issuances (2015 - 2025) Analysis & Trends
BeOne Medicines (ONC) has reported Long-Term Debt Issuances for 10 consecutive years, with $26.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances rose 187.2% year-over-year to $26.0 million; the TTM figure through Dec 2025 stood at $911.0 million (up 9962.96% YoY), while the FY2025 annual figure was $911.0 million, up 9962.96% from the prior year.
- Long-Term Debt Issuances declined to $26.0 million in Q4 2025 per ONC's latest filing, from $885.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $885.0 million in Q3 2025 and bottomed at -$22.5 million in Q4 2023.
- Historically, Long-Term Debt Issuances has averaged $81.2 million across 5 years, with a median of $9.1 million in 2024.
- Annual changes were most pronounced in 2024 — Long-Term Debt Issuances sank 234.5% — and 2025, when it jumped 9875.76%.
- BeOne Medicines' Long-Term Debt Issuances stood at $6.0 million in 2021, then surged by 520.9% to $37.4 million in 2022, then slumped by 160.21% to -$22.5 million in 2023, then surged by 140.23% to $9.1 million in 2024, then soared by 187.2% to $26.0 million in 2025.
- Business Quant data shows ONC's Long-Term Debt Issuances at $26.0 million in Q4 2025, $885.0 million in Q3 2025, and $9.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.00 Mn |
| Dec 31, 2025 | 26.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Dec 31, 2024 | 9.05 Mn |
| Dec 31, 2024 | 9.05 Mn |
| Sep 30, 2024 | -9.05 Mn |
| Sep 30, 2024 | -9.05 Mn |
| Mar 31, 2024 | 9.05 Mn |
| Mar 31, 2024 | 9.05 Mn |
| Dec 31, 2023 | -22.50 Mn |
| Dec 31, 2023 | -22.50 Mn |
| Sep 30, 2023 | 6.73 Mn |
| Sep 30, 2023 | 6.73 Mn |
| Jun 30, 2023 | 15.77 Mn |
| Jun 30, 2023 | 15.77 Mn |
| Sep 30, 2022 | 37.37 Mn |
| Sep 30, 2022 | 37.37 Mn |
| Sep 30, 2021 | 6.02 Mn |
| Sep 30, 2021 | 6.02 Mn |